Tzivelekis S, Orange J, Poulos C, Meckley LM, Peay H, Sutphin J, Hernandez-Trujillo VP, Wasserman RL. Development of a novel shared decision making aid for primary immunodeficiency diseases. Immunotherapy. 2023 Jun;15(9):647-56. doi: 10.2217/imt-2022-0193
Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265
Curran D, Patterson B, Carrico J, Salem A, La E, Lorenc S, Hicks K, Poston S, Carpenter C. Cost-effectiveness analysis of recombinant Zoster vaccine for the prevention of herpes Zoster in immunocompromised adults diagnosed with select cancers in the United States. Poster presented at the 2021 Lymphoma and Myeloma (L&M) Virtual Congress; October 2021. [abstract] Am J Hematol. 2021 Oct 15; 96(S1):S26. doi: 10.1002/ajh.26351
Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Candrilli SD, O'Brien S, Ware RE, Balkrishnan R. Hydroxyurea adherence and associated outcomes in medicaid enrollees with sickle cell disease. Am J Hematol. 2011 Feb;86(3):273-7. doi: 10.1002/ajh.21968
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.
Hershey N, Cann CI, Rothman KJ. Reply: overcoming hurdles to epidemiologic research. E & HR. 1985 Mar;7(2):9. doi: 10.2307/3564146
Cann CI, Rothman KJ. IRBs and epidemiologic research: how inappropriate restrictions hamper studies. E & HR. 1984 Jul;6(4):5-7. doi: 10.2307/3564590